Royal Philips, the parent company of Philips Healthcare, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its ElastQ Imaging capability, part of its Epiq ultrasound suite.
ElastQ Imaging uses shear-wave elastography and enables simultaneous imaging of tissue and assessment of its stiffness for evaluating liver disease.
The new device offers a large field-of-view or region of interest, color-coded quantitative assessment of tissue stiffness, real-time feedback and intelligent analysis, and quantitative measurements with multiple sample points, Philips said.
